NICE Rejects Keytruda/Inlyta Combo First-Line In RCC
More Mature Evidence Needed Says Draft Guidance
The cost-effectiveness of combination therapies for untreated advanced renal cell carcinoma therapies comes under the spotlight as England's HTA body rejects an immunotherapy/kinase inhibitor combination in draft guidance.
You may also be interested in...
UCB's R&D efforts include late-stage diverse but complementary immunologicals and anti-neuroinflammatories.
Deal Snapshot: AstraZeneca has sublicensed global rights to its peripheral mu-opioid receptor antagonist to RedHill Biopharma, excluding Europe, Canada and Israel, with RedHill also separately receiving non-dilutive financing from HealthCare Royalty Partners.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.